Rakovina Therapeutics receives 30-day extension for private placement

Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) received a 30-day extension from the TSX Venture Exchange for its non-brokered private placement financing. The offering is now expected to close on or before April 9, 2026.

The biopharmaceutical company intends to raise up to $1 million through the offering of up to 8,333,334 common shares at $0.12 per share. The company may pay finder's fees to certain eligible finders who introduce subscribers to the financing.

Rakovina plans to use the net proceeds to provide working capital for ongoing corporate activities and strategic initiatives while evaluating longer-term financing alternatives. The company had previously announced the private placement on January 27, 2026 and February 20, 2026.

The Vancouver-based company focuses on developing cancer treatments using artificial intelligence-powered drug discovery platforms. Rakovina has established a pipeline of DNA-damage response inhibitors with the goal of advancing drug candidates into human clinical trials in collaboration with pharmaceutical partners.

You May Also Be Interested In

• Csquare prices IPO at $21 per share on NYSE
• ASP Isotopes to swap $109M in QLE notes for common stock
• Scorpio Gold ups public offering to $10M amid investor demand